Healthcare Providers and Services
Company Overview of Progyny, Inc.
Progyny, Inc. operates as a healthcare company that provides fertility services to consumers, employers, and health plans. It offers a non-invasive time-lapse imaging system to aid in the early embryo selection; a no-restriction IVF package plan for patients; egg freezing options through its network of fertility doctors across the United States; and a patient-matching technology platform for the fertility industry. Progyny, Inc. has a strategic alliance with Mercer L.L.C. Progyny, Inc. was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in April 2015. The company was incorporated in 2008 and is based in New York, New York with operations in San Francisco and Menlo Park,...
99 Hudson Street
New York, NY 10013
Founded in 2008
Key Executives for Progyny, Inc.
Chief Executive Officer and Director
President of Healthcare Services
Senior Vice President of Clinical Affairs
Compensation as of Fiscal Year 2016.
Progyny, Inc. Key Developments
Progyny Announces New Study That Will Further Aid Embryo Screening with the Use of Progyny’s Eeva™ Test for in Vitro Fertilization Patients
Jul 12 16
Progyny announced a new study that will further aid embryo screening with the use of Progyny’s Eeva™ (early embryo viability assessment) Test for in vitro fertilization (IVF) patients. The study was presented at the European Society of Human Reproduction and Embryology’s (ESHRE) annual conference in Helsinki, Finland. The study focused on identifying specific markers of chromosomally normal blastocysts to determine which chromosomally normal embryos implanted and led to a live birth versus similar embryos that did not lead to a live birth. These markers were identified using the Eeva Test, the only FDA cleared, non-invasive early embryo screening tool. This analysis lays a foundation to further assist embryologists with determining a patient’s embryo transfer order. The study was designed to further enhance the performance of current embryo screening techniques to better understand which chromosomally normal embryos are likely to lead to a live birth. The study analyzed 55 patients with 81 transferred euploid blastocysts from fresh and frozen cycles from 2012 to 2013. Out of the 81 blastocysts transferred, 43 led to a live birth. Eeva’s Time Lapse System automatically processed embryo markers looking at dynamic blastocyst development including the number, frequency, timing and rate of collapses during embryo culture. The study determined that euploid blastocysts with more frequent and longer blastocyst collapse events have a lower live birth rate when compared to similar embryos that implanted and led to a live birth. This dynamic blastocyst marker, termed High Collapse Index by the authors, may compromise embryo viability or may be a new mark of embryo quality.
Merck & Co. Inc. Extends Collaboration Agreement with Progyny, Inc
May 12 16
Merck & Co., Inc. has extended its collaboration agreement with Progyny, Inc. for Eeva Software. Under the new agreement, effective immediately, Merck receives global marketing and commercialization rights for Progyny's Early Embryo Viability Assessment (Eeva) software offering, an important tool for clinicians and laboratories in assisted reproductive treatment (ART). The former agreement had granted Merck exclusive rights to commercialize the Eeva Test in Europe and Canada, with the option to extend to selected countries. The renewed collaboration allows Merck non-exclusive, worldwide rights to the Eeva Test which will further strengthen its leadership position in the global fertility technologies market and provide customers worldwide with innovative solutions, aiming to further improve outcomes for patients undergoing ART. The advanced Eeva software offering ensures high usability and flexibility for clinicians and laboratories. It provides reproductive endocrinologists and embryologists with detailed information and a better basis for decision-making. The software objectively identifies embryos that have a high potential to become blastocysts, ultimately helping to increase the chances for embryo implantation. At the same time, the software can be integrated into existing clinic routines and is flexible with use of new hardware.
Mercer Forms Strategic Alliance with Progyny to Offer Innovative Fertility Benefits
Jan 7 16
Mercer announced it has formed a strategic alliance with Progyny to provide employers and their employees with the innovative SMART™ (Science and Member-Driven Assisted Reproductive Technology) fertility benefit product which will enable companies to significantly reduce newborn intensive care unit (NICU) and associated high-risk maternity-related costs, while increasing access and positive outcomes. The Progyny Suite of SMART Fertility Services includes a comprehensive national network of fertility clinics; clinic quality and cost transparency; and personal concierge services delivered by Patient Care Advocates. Benefits include: egg freezing, IVF treatment, non-IVF fertility treatments, and medications. In addition, genetic counselors, fertility nurses, psychologists, and surrogacy counselors will be available to patients for an end-to-end fertility solution. Employees and employers will also have access to the Progyny Patient Portal with over 250,000 pages of fertility information and education.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 15, 2016